Merck announced preliminary data suggesting the drug reduced the risk of hospitalisation and death by 50%.
Academic rigor, journalistic flair
Articles on Phase 3 Trial
Displaying all articles
We need more data on the low-dose, high-dose regimen used in one arm of the trial, which may make the vaccine more effective.
COVID-19 vaccines are at risk of being undermined by vaccine hesitancy. Pharma must take steps to ensure transparency in data monitoring committees and trial data to build public trust in vaccines.
Several vaccines are in Phase 3 trials. So when will we know whether any of these will protect against COVID-19?
Stoppages of clinical trials are a normal part of the testing process, and show that patient safety is being taken seriously.
As Russia fast tracks a coronavirus vaccine, scientists worry about skipped safety checks – and the potential fallout for trust in vaccines if something ends up going wrong.
Drugs and vaccines to fight the coronavirus are already in clinical trials. It is important to understand the difference between each step in this process as efforts to fight COVID-19 continue.
Vaccine development is usually a long process. The coronavirus pandemic is forcing researchers to innovate and test potential vaccines faster than ever before.
Top contributors
-
Professor of Molecular and Cell Biology, University of California, Merced
-
Professor of medicine, epidemiology & biostatistics, and philosophy, Western University
-
Professor of Medicine, University of East Anglia
-
Associate Professor of Bioethics, University of Portsmouth
-
Professor of Medicine, University of Virginia
-
Professor and Director - Academic Excellence, Macquarie University
-
Program Administrator, University of Southern California
-
Clinical Professor of Neurology, University of Southern California
-
Research Assistant Professor of Epidemiology, University of Michigan
